Aadi Bioscience, Inc. (NASDAQ:AADI) Q2 2023 Earnings Conference Call August 9, 2023 8:30 AM ET
Company Participants
Marcy Graham - SVP of IR and Corporate Communications
Scott Giacobello - Interim CEO, President, and CFO
Loretta Itri - Chief Medical Officer
Conference Call Participants
Joseph Catanzaro - Piper Sandler
Ahu Demir - Ladenburg Thalmann & Company
Boris Peaker - Cowen and Company
Roger Song - Jefferies LLC
Operator
Good day, and thank you for standing by. Welcome to the Aadi Bioscience, Incorporated Second Quarter 2023 Earnings Call. At this time all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to Marcy Graham, Senior Vice President of Investor Relations and Corporate Communications at Aadi Biosciences. Ms. Graham?
Marcy Graham
Thank you. Good morning, and welcome to the Aadi Bioscience conference call to provide an operational update and review results of the second quarter 2023. Joining me on the call today is Scott Giacobello, our CFO and Interim President and CEO, who will provide an overview of financial and operational activity during the period, including an update on our continued commercial progress. And he will be followed by our Chief Medical Officer, Dr. Loretta Itri, who will provide an update on our PRECISION 1 study and clinical development plans for 2023. We will open the line for questions at the end of the call following closing comments.
A quick reminder that statements made on the call today will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in the Risk Factors section of our annual and quarterly filings with the Securities and Exchange Commission, which can be found at www.sec.gov or on our website at www.aadibio.com.
In addition, any forward-looking statements made on this call represent our views only as of today, August 9, 2023, and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements.
With that, I will turn the call over to Scott for his opening comments. Scott?
Scott Giacobello
Thank you, Marcy, and good morning, everyone. Thank you for joining us today to review our financial and operational results for the second quarter of 2023. We continue to see solid performance from our commercial and clinical organizations during the quarter, each focused on driving results as we enter the second half of the year.